Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 544009 | NSE: BLUEJET

Blue Jet Healthcare Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 11, 2025, 11:40 pm

Market Cap 14,204 Cr.
Current Price 819
High / Low 871/329
Stock P/E60.5
Book Value 53.3
Dividend Yield0.12 %
ROCE30.0 %
ROE22.4 %
Face Value 2.00
PEG Ratio9.11

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Blue Jet Healthcare Ltd

Competitors of Blue Jet Healthcare Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,253.28 Cr1,081.5542.44185.800.37%16.00%16.32%6.27

All Competitor Stocks of Blue Jet Healthcare Ltd

Quarterly Result

MetricJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 145190169217180181167184163208318
Expenses 106132117147121119112131119139194
Operating Profit 38595270596355534469124
OPM % 27%31%31%32%33%35%33%29%27%33%39%
Other Income 476658-3991213
Interest 00000000000
Depreciation 66766688355
Profit before tax 36595170586444544977132
Tax % 24%26%27%27%24%26%27%27%24%24%25%
Net Profit 2844385144483240385899
EPS in Rs 1.612.532.162.922.542.761.852.292.183.365.71

Last Updated: February 28, 2025, 12:52 pm

Below is a detailed analysis of the quarterly data for Blue Jet Healthcare Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹318.00 Cr.. The value appears strong and on an upward trend. It has increased from 208.00 Cr. (Sep 2024) to ₹318.00 Cr., marking an increase of ₹110.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹194.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 139.00 Cr. (Sep 2024) to ₹194.00 Cr., marking an increase of ₹55.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹124.00 Cr.. The value appears strong and on an upward trend. It has increased from 69.00 Cr. (Sep 2024) to ₹124.00 Cr., marking an increase of ₹55.00 Cr..
  • For OPM %, as of Dec 2024, the value is 39.00%. The value appears strong and on an upward trend. It has increased from 33.00% (Sep 2024) to 39.00%, marking an increase of 6.00%.
  • For Other Income, as of Dec 2024, the value is ₹13.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Sep 2024) to ₹13.00 Cr., marking an increase of ₹1.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹5.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 5.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹132.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Sep 2024) to ₹132.00 Cr., marking an increase of ₹55.00 Cr..
  • For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Sep 2024) to 25.00%, marking an increase of 1.00%.
  • For Net Profit, as of Dec 2024, the value is ₹99.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Sep 2024) to ₹99.00 Cr., marking an increase of ₹41.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 5.71. The value appears strong and on an upward trend. It has increased from ₹3.36 (Sep 2024) to 5.71, marking an increase of ₹2.35.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 1:44 pm

MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 538499683721712873
Expenses 325292434502482583
Operating Profit 214207249219229291
OPM % 40%41%36%30%32%33%
Other Income 6919241943
Interest 753100
Depreciation 182022252821
Profit before tax 194190243217220313
Tax % 25%26%25%26%26%
Net Profit 145142182160164235
EPS in Rs 24,118.331,428.5710.479.239.4413.54
Dividend Payout % 0%0%0%0%11%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-2.07%28.17%-12.09%2.50%
Change in YoY Net Profit Growth (%)0.00%30.24%-40.26%14.59%

Blue Jet Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2020-2021 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:%
3 Years:13%
TTM:17%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:7%
TTM:29%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:%
1 Year:139%
Return on Equity
10 Years:%
5 Years:%
3 Years:28%
Last Year:22%

Last Updated: Unknown

Balance Sheet

Last Updated: January 8, 2025, 9:14 am

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 0.601035353535
Reserves 198330487647811889
Borrowings 745319531
Other Liabilities 92143173176211256
Total Liabilities 3645367138621,0591,181
Fixed Assets 1070156151172268
CWIP 2333014785
Investments 263794189250293
Other Assets 229497460491489535
Total Assets 3645367138621,0591,181

Below is a detailed analysis of the balance sheet data for Blue Jet Healthcare Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹35.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹889.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹811.00 Cr. (Mar 2024) to ₹889.00 Cr., marking an increase of 78.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹1.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹3.00 Cr. (Mar 2024) to ₹1.00 Cr., marking a decrease of 2.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹256.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹211.00 Cr. (Mar 2024) to ₹256.00 Cr., marking an increase of 45.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹1,181.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,059.00 Cr. (Mar 2024) to ₹1,181.00 Cr., marking an increase of 122.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹268.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹172.00 Cr. (Mar 2024) to ₹268.00 Cr., marking an increase of 96.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹85.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹147.00 Cr. (Mar 2024) to ₹85.00 Cr., marking a decrease of 62.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹293.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹250.00 Cr. (Mar 2024) to ₹293.00 Cr., marking an increase of 43.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹535.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹489.00 Cr. (Mar 2024) to ₹535.00 Cr., marking an increase of 46.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹1,181.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,059.00 Cr. (Mar 2024) to ₹1,181.00 Cr., marking an increase of 122.00 Cr..

Notably, the Reserves (₹889.00 Cr.) exceed the Borrowings (1.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +122137146142241
Cash from Investing Activity +-45-61-76-147-264
Cash from Financing Activity +-72-21-56-4-2
Net Cash Flow55514-10-24

Free Cash Flow

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow140.00154.00230.00214.00226.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days8010512112191
Inventory Days120201133137151
Days Payable90101725835
Cash Conversion Cycle110204183199206
Working Capital Days6410510512193
ROCE %58%52%35%30%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters86.00%86.00%86.00%86.00%86.00%
FIIs2.93%2.01%2.02%2.18%1.10%
DIIs3.70%3.04%2.14%1.75%2.02%
Public7.37%8.97%9.83%10.06%10.87%
No. of Shareholders55,58948,62542,88241,93343,003

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund1,080,4131.0137.17732,0672025-03-1047.58%
ICICI Prudential Innovation Fund732,0670.625.18732,0672025-03-100%
HDFC Business Cycle Fund367,3440.4312.64732,0672025-03-10-49.82%
Bandhan Small Cap Fund285,3910.229.82732,0672025-03-10-61.02%
Edelweiss Recently Listed IPO Fund231,4030.847.96732,0672025-03-10-68.39%
Edelweiss Aggressive Hybrid Fund144,4800.374.97732,0672025-03-10-80.26%
Edelweiss Aggressive Hybrid Fund - Plan B144,4800.374.97732,0672025-03-10-80.26%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 21Mar 20
FaceValue 100.00100.00
Basic EPS (Rs.) 1396.271462.59
Diluted EPS (Rs.) 1396.271462.59
Cash EPS (Rs.) 1568.3027166.33
Book Value[Excl.RevalReserv]/Share (Rs.) 3428.3432238.33
Book Value[Incl.RevalReserv]/Share (Rs.) 3428.3432238.33
Revenue From Operations / Share (Rs.) 5033.6189699.16
PBDIT / Share (Rs.) 2168.4336589.16
PBIT / Share (Rs.) 1970.0533582.66
PBT / Share (Rs.) 1862.9632354.50
Net Profit / Share (Rs.) 1369.9224159.83
NP After MI And SOA / Share (Rs.) 1396.4324141.33
PBDIT Margin (%) 43.0740.79
PBIT Margin (%) 39.1337.43
PBT Margin (%) 37.0136.07
Net Profit Margin (%) 27.2126.93
NP After MI And SOA Margin (%) 27.7426.91
Return on Networth / Equity (%) 40.7375.40
Return on Capital Employeed (%) 52.3283.21
Return On Assets (%) 25.9438.58
Long Term Debt / Equity (X) 0.080.19
Total Debt / Equity (X) 0.100.30
Asset Turnover Ratio (%) 1.100.00
Current Ratio (X) 2.431.89
Quick Ratio (X) 1.691.37
Inventory Turnover Ratio (X) 2.300.00
Interest Coverage Ratio (X) 40.4929.79
Interest Coverage Ratio (Post Tax) (X) 27.5820.67

After reviewing the key financial ratios for Blue Jet Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 21, the value is 100.00. This value exceeds the healthy maximum of 10. There is no change compared to the previous period (Mar 20) which recorded 100.00.
  • For Basic EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
  • For Diluted EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
  • For Cash EPS (Rs.), as of Mar 21, the value is 1,568.30. This value is within the healthy range. It has decreased from 27,166.33 (Mar 20) to 1,568.30, marking a decrease of 25,598.03.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
  • For Revenue From Operations / Share (Rs.), as of Mar 21, the value is 5,033.61. It has decreased from 89,699.16 (Mar 20) to 5,033.61, marking a decrease of 84,665.55.
  • For PBDIT / Share (Rs.), as of Mar 21, the value is 2,168.43. This value is within the healthy range. It has decreased from 36,589.16 (Mar 20) to 2,168.43, marking a decrease of 34,420.73.
  • For PBIT / Share (Rs.), as of Mar 21, the value is 1,970.05. This value is within the healthy range. It has decreased from 33,582.66 (Mar 20) to 1,970.05, marking a decrease of 31,612.61.
  • For PBT / Share (Rs.), as of Mar 21, the value is 1,862.96. This value is within the healthy range. It has decreased from 32,354.50 (Mar 20) to 1,862.96, marking a decrease of 30,491.54.
  • For Net Profit / Share (Rs.), as of Mar 21, the value is 1,369.92. This value is within the healthy range. It has decreased from 24,159.83 (Mar 20) to 1,369.92, marking a decrease of 22,789.91.
  • For NP After MI And SOA / Share (Rs.), as of Mar 21, the value is 1,396.43. This value is within the healthy range. It has decreased from 24,141.33 (Mar 20) to 1,396.43, marking a decrease of 22,744.90.
  • For PBDIT Margin (%), as of Mar 21, the value is 43.07. This value is within the healthy range. It has increased from 40.79 (Mar 20) to 43.07, marking an increase of 2.28.
  • For PBIT Margin (%), as of Mar 21, the value is 39.13. This value exceeds the healthy maximum of 20. It has increased from 37.43 (Mar 20) to 39.13, marking an increase of 1.70.
  • For PBT Margin (%), as of Mar 21, the value is 37.01. This value is within the healthy range. It has increased from 36.07 (Mar 20) to 37.01, marking an increase of 0.94.
  • For Net Profit Margin (%), as of Mar 21, the value is 27.21. This value exceeds the healthy maximum of 10. It has increased from 26.93 (Mar 20) to 27.21, marking an increase of 0.28.
  • For NP After MI And SOA Margin (%), as of Mar 21, the value is 27.74. This value exceeds the healthy maximum of 20. It has increased from 26.91 (Mar 20) to 27.74, marking an increase of 0.83.
  • For Return on Networth / Equity (%), as of Mar 21, the value is 40.73. This value is within the healthy range. It has decreased from 75.40 (Mar 20) to 40.73, marking a decrease of 34.67.
  • For Return on Capital Employeed (%), as of Mar 21, the value is 52.32. This value is within the healthy range. It has decreased from 83.21 (Mar 20) to 52.32, marking a decrease of 30.89.
  • For Return On Assets (%), as of Mar 21, the value is 25.94. This value is within the healthy range. It has decreased from 38.58 (Mar 20) to 25.94, marking a decrease of 12.64.
  • For Long Term Debt / Equity (X), as of Mar 21, the value is 0.08. This value is below the healthy minimum of 0.2. It has decreased from 0.19 (Mar 20) to 0.08, marking a decrease of 0.11.
  • For Total Debt / Equity (X), as of Mar 21, the value is 0.10. This value is within the healthy range. It has decreased from 0.30 (Mar 20) to 0.10, marking a decrease of 0.20.
  • For Asset Turnover Ratio (%), as of Mar 21, the value is 1.10. It has increased from 0.00 (Mar 20) to 1.10, marking an increase of 1.10.
  • For Current Ratio (X), as of Mar 21, the value is 2.43. This value is within the healthy range. It has increased from 1.89 (Mar 20) to 2.43, marking an increase of 0.54.
  • For Quick Ratio (X), as of Mar 21, the value is 1.69. This value is within the healthy range. It has increased from 1.37 (Mar 20) to 1.69, marking an increase of 0.32.
  • For Inventory Turnover Ratio (X), as of Mar 21, the value is 2.30. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 20) to 2.30, marking an increase of 2.30.
  • For Interest Coverage Ratio (X), as of Mar 21, the value is 40.49. This value is within the healthy range. It has increased from 29.79 (Mar 20) to 40.49, marking an increase of 10.70.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 21, the value is 27.58. This value is within the healthy range. It has increased from 20.67 (Mar 20) to 27.58, marking an increase of 6.91.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Blue Jet Healthcare Ltd as of March 12, 2025 is: ₹578.55

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Blue Jet Healthcare Ltd is Overvalued by 29.36% compared to the current share price 819.00

Intrinsic Value of Blue Jet Healthcare Ltd as of March 12, 2025 is: 616.96

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Blue Jet Healthcare Ltd is Overvalued by 24.67% compared to the current share price 819.00

Last 5 Year EPS CAGR: 6.64%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock is trading at a low valuation with an average P/B ratio of 17,776.36 and average Dividend Yield of 38.28%.
  2. The stock has a high average ROCE of 35.00%, which is a positive sign.
  3. The company has higher reserves (560.33 cr) compared to borrowings (25.83 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (671.00 cr) and profit (229.50 cr) over the years.
  1. The stock has a high average Working Capital Days of 97.60, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 180.40, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Blue Jet Healthcare Ltd:
    1. Net Profit Margin: 27.21%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 52.32% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 40.73% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 27.58
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.69
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 60.5 (Industry average Stock P/E: 42.44)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.1
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Blue Jet Healthcare Ltd is a Public Limited Listed company incorporated on 07/12/1968 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1968PLC014154 and registration number is 014154. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company's Total Operating Revenue is Rs. 711.60 Cr. and Equity Capital is Rs. 34.69 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Pharmaceuticals701, 702, 7th Floor, Navi Mumbai Maharashtra 400705companysecretary@bluejethealthcare.com
http://www.bluejethealthcare.com
Management
NamePosition Held
Mr. Akshay Bansarilal AroraExecutive Chairman
Mr. Shiven Akshay AroraManaging Director
Mr. Naresh Suryakant ShahExecutive Director
Ms. Divya Sameer MomayaIndependent Director
Mr. Girish Paman VanvariIndependent Director
Ms. Preeti Gautam MehtaIndependent Director

FAQ

What is the latest intrinsic value of Blue Jet Healthcare Ltd?

The latest intrinsic value of Blue Jet Healthcare Ltd as on 12 March 2025 is ₹578.55, which is 29.36% lower than the current market price of 819.00, indicating the stock is overvalued by 29.36%. The intrinsic value of Blue Jet Healthcare Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹14,204 Cr. and recorded a high/low of ₹871/329 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹889 Cr and total liabilities of ₹1,181 Cr.

What is the Market Cap of Blue Jet Healthcare Ltd?

The Market Cap of Blue Jet Healthcare Ltd is 14,204 Cr..

What is the current Stock Price of Blue Jet Healthcare Ltd as on 12 March 2025?

The current stock price of Blue Jet Healthcare Ltd as on 12 March 2025 is ₹819.

What is the High / Low of Blue Jet Healthcare Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Blue Jet Healthcare Ltd stocks is ₹871/329.

What is the Stock P/E of Blue Jet Healthcare Ltd?

The Stock P/E of Blue Jet Healthcare Ltd is 60.5.

What is the Book Value of Blue Jet Healthcare Ltd?

The Book Value of Blue Jet Healthcare Ltd is 53.3.

What is the Dividend Yield of Blue Jet Healthcare Ltd?

The Dividend Yield of Blue Jet Healthcare Ltd is 0.12 %.

What is the ROCE of Blue Jet Healthcare Ltd?

The ROCE of Blue Jet Healthcare Ltd is 30.0 %.

What is the ROE of Blue Jet Healthcare Ltd?

The ROE of Blue Jet Healthcare Ltd is 22.4 %.

What is the Face Value of Blue Jet Healthcare Ltd?

The Face Value of Blue Jet Healthcare Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Blue Jet Healthcare Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE